At Clinicom Healthcare, our mission is to champion mental health equity and accessibility for all! We dedicated nearly 15 years meticulously refining Clinicom through clinical validations, peer-reviewed publications, and rigorous testing, ensuring we adhered to the highest clinical and scientific standards.
Our commitment to helping individuals find answers takes precedence over profits. To uphold this mission, we've made our product widely available by offering a free trial and an affordable per-patient unlimited use pricing structure. At Clinicom, we work tirelessly to ensure mental health care is within reach for everyone.
Clinicom’s Team have been an integral part of some of the most sensitive and pivotal independent CNS Clinical Trials supporting pharma companies drug development for the last 20 years. Pharma has trusted our team with their most sensitive IP and the responsibility of accurately measuring mental health for FDA trials for two decades. In 2022, Clinicom CEO Ignacio Handal was awarded the Christine Pierre Lifetime Achievement Award in Clinical Research, This global award recognized his ongoing contribution to FDA Clinical Trials that has positively impacted 200 million lives through a myriad of drug and device approvals. This award is the highest honor in Clinical Trial Research globally.
As reported by Globaldata.com, our Founders, Chairman, CEO, CMO, and Director of Research have each independently conducted more pharma clinical trial research than 99.2% of all Global PIs, SubIs, and other Researchers combined, across all therapeutic areas. Part of the reason pharma has repeatedly selected our independent CNS research site is because of the Clinicom platform we developed through our CRO, and the sophisticated screening tools we developed to screen and measure mental health, earning us a strong reputation within FDA clinical trials, Pharma, life sciences, and the CRO space.
Clinicom is composed of compassionate healthcare professionals, mental health innovation leaders and pioneering technology developers.
Nelson M. Handal, MD attended Medical School at the Ruprecht Karl University in Heidelberg, Germany, and graduated from Universidad Mayor de San Andres in La Paz-Bolivia, his hometown. He completed his internship and residency training in General Psychiatry at the State University of New York Health Science Center at Syracuse in Syracuse, New York. Following residency, he completed his Fellowship in Child and Adolescent Psychiatry at the University of Miami School of Medicine in Miami, Florida. At the present time he is a Clinical Faculty at the Alabama College of Osteopathic Medicine in Dothan, Alabama.
His vision to create CliniCom® was born after many years of work focused on perfecting a mental health clinical model that uses technology while implementing sensible, practical, and modern clinical practices. Developing CliniCom® for over 10 years has been for him the most challenging and expensive endeavor, but it led to an article in Forbes in 2018 after CliniCom® was used by thousands of patients around the US. Clinicom was also awarded at the Psychiatry Innovation Lab at the American Psychiatric Association. Dr. Handal was invited to testify before the United States House Committee on Veterans’ Affairs regarding innovative technologies and treatments for veterans; he spoke about CliniCom®.
For the past 20 years, Dr. Nelson M. Handal has been the Founder, Chairman, and Medical Director for Dothan Behavioral Medicine Clinic a large and modern mental health clinic. Four physicians, two nurse practitioners and thirteen therapists serve about 180 patients a day, half of whom live more than an hour away.
He is also the Founder and Medical Director of Harmonex Neuroscience Research where he participated in clinical research as a primary investigator in over 80 clinical trials for the past 14 years. He was Chief Medical Officer with NLS Pharmaceutics from Switzerland in a critical award-winning research study.
Dr. Handal has dedicated much of his career to developing and implementing technologies that elevate the quality of patient care. In the late 1980s, Dr. Handal was president of one of the first international telemedicine referral services in the world. This system was featured in Business Week.
Awards include the Heroes in the Fight Award given by Mental Health America. Excellence in Public Mental Health Award given by the National Alliance on Mental Illness (NAMI). In addition, Dr. Handal has been recognized as one of America’s Top Psychiatrists given by the Consumers’ Research Council of America. Dr. Handal has also received the Patient’s Choice Award and the Mental Health Professional of the Year Award for Alabama. He was presented with the Clinical Scholar Award conferred by the University of Miami School of Medicine. His private practice, Dothan Behavioral Medicine Clinic, has received the Best of Dothan Award in the Physicians' category by the U.S. Local Business Association (USLBA). Dr. Handal is a Distinguished Fellow of the American Psychiatric Association and Diplomate of the American Board of Psychiatry and Neurology.
Ignacio Handal is the CEO at Clinicom Healthcare. Ignacio has completed a multitude of FDA phase I, II, & III studies in pharmaceuticals, and devices over two decades. Ignacio has completed more Pharma sponsored clinical research studies than 99.8% of all clinical researchers internationally per globaldata.com Mr. Handal has completed clinical studies that have help put a myriad of drugs and devices to market over the last twenty years, These products have touched the lives of over a two hundred million patients. In 2022 Ignacio was honored with one of the highest honors in Clinical Research, the Christine Pierre Clinical trials lifetime achievement award. Only 8 clinical researchers globally have ever been awarded this honor.
Mr. Handal has led the creation and development of two nationally recognized US clinical research centers, Harmonex Neuroscience Research and Trinity Research at Eye Center South. Harmonex Neuroscience is the clinical research institute that gave birth to Clinicom at its inception, Prior to Clinicom, Ignacio was Director of Clinical Project Management and Director of Program Management at Biorasi, a global CRO. He was Director of Clinical Research at Eye Center South the Third largest surgical center ASC in the USA from 2015-8/2018 where he founded their research division.
Ignacio and his team have used the profits of their research trials over the last twenty years to develop the world's first online mental health assessment software that can assess anyone remotely for 81 mental health conditions in one virtual adaptive ML assessment. Clinicom has helped patients all over the world find answers on their mental health journey. Clinicom has also helped accelerate enrollment and patient identification for precise inclusion and exclusion criteria in phase II and III studies in the US. The Clinicom mission is to give every patient a voice and to bring equity and access to mental health. Clinicom currently serves patients in 6 continents.
In addition to providing advice to Clinicom through service on the Board of Directors; James Riddle is the Vice President for Research Services & Strategic Consulting for Advarra where he employs his extensive experience managing large operations and technology teams in the human subject protection, research administration, and regulatory fields to grow Advarra worldwide. Mr. Riddle is also a faculty member, mentor, and regular speaker for Public Responsibility in Medicine and Research (PRIM&R); a member of the CTTI Steering Committee; and leader of the SASI technology domain accreditation team.
Prior to joining Advarra, Mr. Riddle served as a leader of the human subject protection and animal care and use program at the Fred Hutchinson Cancer Research Center, one of the nation’s largest independent cancer research centers. In addition, he has served on the board of the Northwest Association for Biomedical Research (NWABR), was an AAHRPP site visitor, and was the Vice President of Operations and Director of Technology at another large central IRB. His expertise includes reengineering operational processes, systems evaluations, development and implementation of technology solutions, integration of technology solutions with operations, and management of large IRB and IACUC systems.
Mr. Riddle has a bachelor’s degree in accounting with an emphasis in computer science from Western Washington University, College of Business and Economics.
Dr. McCleod is a Board Certified Child and Adolescent Psychiatrist who has been in practice since 2003. She is the Chief Medical officer for Clinicom Healthcare Inc. She is a investigator in many clinical research studies. Dr. McCleod is the current Medical Director of Southeast Alabama Youth Services' Diversion Center and the Boys and Girls Attention Group Homes. She is owner and founder of J.C. McCleod, MD Psychiatric, PLLC. She serves as a clinical faculty member for the Alabama College of Osteopathic Medicine supervising medical students. She also supervises nursing, counseling, and social work students in the field of psychiatry as a clinical preceptor. She has recently retired from Laurel Oaks Behavioral Health Center, an acute and residential in-patient psychiatric care for children and adolescents, where she was the Medical Director from 2009-2020. She is the former medical director of Bradford Health Clinic, an intensive out-patient center for treatment of adults and adolescents with substance dependence in Dothan, Alabama from 2006-2018.
She is a native of Chicago, Illinois and completed her Bachelor of Science Degree at Howard University in Washington, DC. She received her Medical Degree from the University of Illinois, College of Medicine. She completed her residency in General Psychiatry, and fellowship in Child and Adolescent Psychiatry both at Emory University in Atlanta, Georgia. Dr. McCleod is Board Certified in General Psychiatry as well as Child and Adolescent Psychiatry. She is licensed to practice medicine in the states of Alabama and Georgia.
Dr. McCleod is a Fellow of the American Psychiatric Association, and a member in good standing of the American Academy of Child and Adolescent Psychiatrists, the American Medical Association and the National Medical Association. She is a life member of the Global Directory of Who's Who in American Professionals. She received the Mental Health Professional of the Year Award given by the National Alliance for the Mentally Ill (NAMI), Wiregrass in 2009. She was on the board of directors for NAMI Alabama from 2017-2019.
She served as the 12th and again as the 14th chapter President of Alpha Kappa Alpha Sorority, Incorporated, Kappa Pi Omega Chapter, and was voted as the chapter's 2010 “Soror of the Year”. She actively volunteers in many community service projects. She's a member of Greater Beulah Baptist Church. She is married to Don McCleod, CPA, and they have two children, Don Robert and Michelle.
Michael Gronau is Director of Finance with Clinicom Healthcare, Inc.
He is presently helping to drive the financial planning and fundraising strategy of the company by building out the financial projections, analyzing performance and suggesting appropriate funding strategies for Clinicom.
Presently, Michael also serves as an elected official on the town council in his home town. On council Michael serves as Council President, Chairman of the Finance Committee, Water Commissioner and is responsible for the town’s technology infrastructure.
Prior to joining Clinicom Michael spent the last 15 years in the private investment banking world working with small boutique firms to help entrepreneurs prepare for private equity investments. Michael’s primary focus and skills were on problem solving, operations and financial modeling.
Michael began his career building a multimillion-dollar enterprise called, On-Site, a service company, that included multiple business arms and a national reach. Michael successfully grew and sold his business at a young age. One of the keys to the success of “On-Site” was the ability to build trust with customers and hosts which translated into lucrative agreements with a litany of Fortune 500 companies like Merck, Johnson & Johnson, Bristol Myers Squibb, ADP, and Merrill Lynch. Michael distinguished his company by providing excellent renowned support and service.
Marcus contributed to the development of the first Internet graphic browser in 1993 and again in 2004 with the propagation of Podcasting. His marketing experience includes work with brands like Nokia, Guitar Center, Farmers Insurance, GoDaddy, AmeriGas and Foot Locker.
Stuart Adams is the Chief Strategy Officer for Clinicom Healthcare Inc. Stuart is a first-round investor in Clinicom and in addition to providing strategic and tactical guidance to the Clinicom Executive Team in the US, Stuart is himself quietly researching and laying foundations for future expansion into EMEA (Europe, Middle East and Africa) so as not to distract from the focus on domestic US activities as Clinicom continues to expand throughout USA.
Based in Edinburgh, Scotland, Stuart is an angel investor and advisor to several entrepreneurial start-up businesses and founders across Health-Tech, Fin-Tech and Capital Markets. Stuart serves as a non-executive director at AKJ Jensen Investment Management and Investment Tribe Limited and advisory board member at SquareBook Limited.
With a background in Financial Markets; over the past 20+ years, Stuart has worked with many founders and their businesses providing strategic advice and insight as they scale. With specific experience in helping businesses land and launch, often advising companies coming to EMEA from the US, he has amassed an extensive network of contacts throughout EMEA and beyond. Stuart has also helped business re-structure, raise finance, and is tightly connected to the investment community and trusted by myriad family offices in EMEA.
Harry is responsible for developing and overseeing Clinicom’s relationships with Customers, Corporations & Family Offices. Harry brings decades of finance and sales experience to the Clinicom team.BBA, Finance & Business Law, University of Cincinnati
Dr. Yach is a former World Health Organization (WHO) cabinet director and executive director for noncommunicable diseases and mental health where he was deeply involved with the development of the world’s treaty on tobacco control, the Framework Convention on Tobacco Control (FCTC). He is also the former Chief Health Officer of the Vitality Group, Executive Director of the Vitality Institute, Senior Vice President, global health and agriculture policy at PepsiCo, director of global health at the Rockefeller Foundation, and a professor of global health at Yale University. He has authored or co-authored more than 250 peer-reviewed articles on global health and has served on several advisory boards, including the World Economic Forum, Cornerstone Capital, and the Wellcome Trust.
As a seasoned commercial leader in Pharma & Biotech, Orchid brings a unique cross-expertise between the Life Sciences and Tech. With deep experience in Marketing Management, Sales Management and Global Brand Strategy at six Fortune 500 pharma companies including Merck, Sanofi, Janssen, Biogen, Novartis and Bayer, she helped bring numerous specialty and primary care treatments to healthcare professionals and patients across various therapeutic areas including Neuroscience, Multiple Sclerosis, Cardiovascular, Wound Care, Oncology and Hematology.
With almost 30 years’ experience in US and Canada in Global Portfolio Strategy, Lifecycle Management, Launch Planning, Sales Engagement and Patient Support Programs, Orchid is a globally-minded leader who moves efficiently between strategic and operational business imperatives. Orchid has a proven eye for organizational talent, having led large sales teams for stellar business results. As the cross-company Champion for Diversity, Equity and Inclusion, she led various educational forums and managerial training at Novartis Canada, and remains deeply committed to DEI as core organizational values.
In 2020, Orchid pivoted her career to the artificial intelligence space at two separate start-ups — to bring the ethical use of AI to healthcare applications (at NuEnergy.AI), and to unleash the power of AI-powered predictive analytics through human-centric pharma tech solutions for the life sciences sector (at ODAIA Intelligence). At ODAIA, Orchid built a strong team of Sales, Operations and Customer Success associates, leading to a 6x YOY growth in only 2 years.
As a Pharma Mentor, Orchid provides advisory services for the Biomedical Engineering Cohort of Creative Destruction Lab (CDL), a global nonprofit organization that provides support for scalable, seed-stage, science- and tech-based startups.
As advisor and investor in various companies including Clinicom, Orchid is passionate to advance early-stage companies that use AI and tech to advance healthcare solutions to reduce patients’ time to therapy.
Orchid sits on the Board of Directors of Kinark Child & Family Services – a leading public organization devoted to mental health of children and youth in the province of Ontario, Canada.
Orchid holds an MBA from the Richard Ivey School of Business and is bilingual in English and French.
Mrs. Baldwin is the Director of Clinical Research for Clinicom Healthcare, Inc. Mrs. Baldwin graduated Summa Cum Laude from Troy University with a Master's degree in Counseling Psychology. She completed a Bachelor of Science in Psychology from Troy State University.
Mrs. Baldwin worked directly with children and adolescents at Harmonex Neuroscience Research and Laurel Oaks Behavioral Health Center.
Mrs. Baldwin began her research career at Harmonex as a research assistant, later becoming a clinical research associate responsible for coordinating a myriad of trials for nearly two decades. Since 2008 she has served as the Director of Clinical Research for Clinicom Healthcare Inc and Harmonex, and oversees the initiation, regulatory documentation, contractual negotiations, and management of all clinical studies.
Mrs. Turner helps to run day to day operations at Clinicom Healthcare, Inc. Angela has been with the company for nearly a decade. She works directly with the public to educate the community about Clinicom, research and our clinical trials through community outreach, health conferences, and volunteering at local non-profit organizations.
She has also been an integral part of developing business relationship with some of the earliest Clinicom Healthcare clients. Her exemplary support and people skills have been a true asset for the company. She believes the road to success and happiness is to live by the 3P's: Practice, Patience and Persistence.
Bill St John is Senior Advisor to Clinicom for Capital Strategies, Life Sciences and Management.
Bill has 25 years of experience in the biotechnology and pharmaceutical business. This experience includes founding four successful biotech firms and serving as incoming CEO for several pharmaceutical firms.
Bill has served as Managing Director of the University Funds, an early-stage venture capital firm and advisor to private equity firms. He is an expert in due diligence, technology transfer, and regular lectures on the subject.
Bill is currently a consultant to select early-stage companies and early-stage venture funds…
Mr. St. John holds a BS degree from Seattle University and an MS in Molecular Biology from The Ohio State University…
Devin is a Fortune seasoned leader experienced in start-up and growth-stage company development. He is passionate about bringing innovative technology and service businesses to market, focused on bridging care gaps and transforming care engagement throughout the continuum.
Devin has an in-depth first-hand knowledge of the State Agency/Payer/Provider/Patient healthcare ecosystem specializing in network development, value-based care, data analytics, cost containment, market strategy, and key stakeholder relationship building.
Devin led go-to-market strategy, analysis, revenue forecasting, operations optimization, and investor presentations. During his time at Baxter Pharmaceutical, Grifols Biopharmaceutical, Fresenius Medical Care, and United Health Group, he secured $4B in annual new business, delivered transformative interventions improving patient utilization metrics by 35%(average), and $400M in cost-containment.
Devin has managed significant P&Ls (from start-up to $100M and had collaborative oversight of $10B) while leading teams to build a national community-based provider network of 4000+ individual organizations. He has successfully managed and mentored teams large (400+) and small across multiple functions and highly matrixed organization and marketplace structures.
First online comprehensive Psychiatric assessment through Clinicom.com.2004
Assessment can screen for up to 50 conditions. Clinicom used as pre-screener for clinical research. Primary clinical testing was conducted at 12 initial clinical beta testing sites.2008
Additional Beta test sites added. Algorithm Builder developed to provide faster, more efficient assessments.2011-2014
All Clinicom algorithms updated from DSM4 to DSM5.2013
Added additional conditions. Upgraded Encryption, HIPAA 2015-16, New R&D Beta Sites added.2015
Alerts, Graphs, Custom Assessments, Additional R&D Beta sites added.2016
Added follow up feature. Clinicom translated to Spanish, Mandarin, Portuguese and Italian.
Clinicom added to Apple Store. Clinicom research study with COPE.2017
After 225,000 suggested diagnosis completed, Clinicom advanced from R&D version 7 to a commercially viable release version.2020
Clinicom V8 adds features such as Life sciences product line, Patient Triage module, Custom assessment templates, more options.
New members added to Executive team, Financial strategy team, Commercial Team and Technology team, Regulatory and Compliance work.
FDA CFR21 part 11. Full Software development life cycle documentation and testing complete.2022
After two decades of meticulous development, rigorous clinical trials, the accumulation of extensive patient data, overcoming numerous technological challenges, and conducting over one million assessments, Clinicom proudly announces the release of its commercial product. This milestone is not just a testament to our technological advancement but a beacon of hope and functionality for providers across the mental health care spectrum and various other industrial verticals. Our journey has been one of perseverance, innovation, and an unwavering commitment to revolutionizing mental health care. Clinicom stands ready to make a difference.2022
Ignacio Handal, CEO of Clinicom, receives the esteemed Christine Pierre Lifetime Achievement Award, underscoring his profound impact on clinical trials and mental health technology. Under his visionary leadership, Clinicom solidifies its position as a revolutionary force in mental health assessments and decentralized trials, harnessing adaptive intelligence technology to screen for a comprehensive range of mental health conditions globally. This distinct accolade has been awarded to just 8 clinical trial innovators from around the globe.Read more2022
Clinicom made a significant stride in mental health innovation by integrating advanced functionality tailored for Transcranial Magnetic Stimulation (TMS) providers. This specialized feature streamlines the patient assessment process, ensuring precise screening and efficient identification of suitable candidates for TMS therapy.2023